• Explore /
  • Poster
  • / Risk factors for venous thromboembolism (VTE) among patients with <em>EGFR</em>-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.

Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.

Abstract Poster

Authors

null

Nicolas Girard

Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France

Nicolas Girard , Byoung Chul Cho , Alexander I. Spira , Catherine A. Shu , Rachel E. Sanborn , Joel W. Neal , Melina Elpi Marmarelis , Joshua K. Sabari , Saiama Naheed Waqar , Misako Nagasaka , James Chih-Hsin Yang , Shun Lu , Pritam Kambuj , Jeffrey Sanchez , Lahila-Carina Ojeda , John Xie , Parthiv Mahadevia , Joshua Michael Bauml , Roland E. Knoblauch , Hidetoshi Hayashi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02609776, NCT04077463, and NCT04075396

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9137)

DOI

10.1200/JCO.2023.41.16_suppl.9137

Abstract #

9137

Poster Bd #

125

Abstract Disclosures

Similar Posters

First Author: Catherine A. Shu

First Author: Se-Hoon Lee

First Author: Keunchil Park

First Author: Sun Min Lim